For clinical applications, BK697 (Fig. S6), a chemical inhibitor of FIRΔexon2, suppressed FIR family expression and tumor cell growth with SAP155 and E-cadherin suppression (Fig. 7c) and increased Snai1 expression (Fig. 7d). This evidence concerns the gene CDH1 and neoplasm.